Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter (NCT06370182) | Clinical Trial Compass
RecruitingNot Applicable
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
United States327 participantsStarted 2024-09-09
Plain-language summary
The objective of this study is to assess the safety and effectiveness of mechanical thrombectomy (MT) using the ANA funnel catheter in its intended use, which is to facilitate the navigation and deployment of other neurovascular devices and to allow flow arrest during mechanical thrombectomy procedures performed in subjects experiencing acute ischemic stroke (AIS) secondary to large vessel occlusion (LVO) and treated within 24 hours of symptom onset.
Who can participate
Age range22 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 22 to 85 years.
✓. Informed consent was obtained from subject or acceptable subject surrogate (e.g., next of kin, or legal representative).
✓. A new focal disabling neurologic deficit consistent with acute cerebral ischemia.
✓. Baseline NIHSS obtained prior to procedure ≥ 6 points and ≤ 25 points.
✓. Pre-ictal mRS score of 0,1 or 2.
✓. Treatable within 16 hours of symptom onset, defined as point in time when the subject was last observed to be asymptomatic; treatment start is defined by arterial puncture time.
✓. If indicated, thrombolytic therapy shall be initiated per the institution's usual care and the most recent version of the AHA/ASA Guidelines. Subjects eligible for IV thrombolysis should receive it without delay.
✓. Occlusion (eTICI ≤ 1 flow) of the terminal carotid artery, middle cerebral artery M1 segment or, dominant or proximal M2 segment, indicated for mechanical thrombectomy, confirmed with conventional angiography or CTA/MRA.
Exclusion criteria
✕. Subject was diagnosed with a stroke in the past year.
✕. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.
✕. Known hemorrhagic diathesis, coagulation factor deficiency, oral anticoagulant therapy with antivitamin K, with INR \>3.0, or thrombocytopenia - baseline platelet count \< 50,000 platelets/mL.
What they're measuring
1
Proportion of subjects with "near-complete" reperfusion after one thrombectomy pass (FPE, eTICI 2c-3, extended Thrombolysis in Cerebral Infarction scale) in the target vessel.
Timeframe: intra-operative
2
Rate of symptomatic intracranial hemorrhage (sICH), attributable to the device or procedure.